Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 1.00 |
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9232780 | 1.00 | HTR2C (1.00) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8959591 | 1.00 | HTR2C (1.00) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| Fumaric Acid SCHEMBL7091387 | 0.88 | HTR2C (0.78) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| Fumaric Acid SCHEMBL7091385 | 0.88 | HTR2C (0.78) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7997689 | 0.87 | HTR2C (0.77) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4033420 | 0.87 | HTR2C (0.77) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8959778 | 0.84 | HTR2C (0.72) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8959781 | 0.84 | HTR2C (0.72) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9233993 | 0.82 | HTR2C (1.00) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9233990 | 0.82 | HTR2C (1.00) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114512-A1 | Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma | ALCON UNIVERSAL LTD. (CH) | 2003-06-19 | — | — | US | claimed |
| EP-1263434-A1 | COMPOUNDS WITH 5-HT 2 AND 5-HT 1A AGONIST ACTIVITY FOR TREATING GLAUCOMA | Alcon, Inc (CH) | 2002-12-11 | — | — | EP | claimed |
| WO-2001070223-A1 | COMPOUNDS WITH 5-HT2 AND 5-HT1A AGONIST ACTIVITY FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | claimed |
| CN-1061341-C | 1-amino-ethylindole-derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-31 | — | — | CN | claimed |
| CN-1105988-A | 1-amino-ethylindole-derivatives | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | claimed |
| EP-0655440-A2 | 1-Aminoethylindoles | F. HOFFMANN-LA ROCHE AG (CH) | 1995-05-31 | — | — | EP | claimed |
| CN-1061341-C | 1-amino-ethylindole-derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-31 | — | — | CN | disclosed |
| US-5494928-A | FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| CN-1105988-A | 1-amino-ethylindole-derivatives | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
| EP-0655440-A2 | 1-Aminoethylindoles | F. HOFFMANN-LA ROCHE AG (CH) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114512-A1 | Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma | HTR1A, HTR2A, HTR5A | HTR2C 6/4885HTR2A 2/4885CYP1A2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.